CD200R1 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CD200R1-Protein</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Suppression</td>
</tr>
<tr>
<td class="label">STAT1</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">NLRP3 inflammasome</td>
<td>Suppression</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CD200R1 agonists</td>
<td>Direct receptor activation</td>
</tr>
<tr>
<td class="label">CD200-Fc</td>
<td>Enhanced CD200 engagement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-CD200R1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">CD200-Fc</td>
<td>Fusion protein</td>
</tr>
<tr>
<td class="label">Anti-CD200R1 mAb</td>
<td>Monoclonal antibody</td>
</tr>
<tr>
<td class="label">CD200R1 mimetic peptides</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Recombinant CD200</td>
<td>Ligand-based</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>
Introduction
CD200 Receptor 1 (CD200R1) is a critical inhibitory immune receptor expressed primarily on microglia and other myeloid cells in the central nervous system. As the receptor for the CD200 (OX-2) glycoprotein, CD200R1 transduces powerful immunosuppressive signals that maintain microglial quiescence and prevent excessive neuroinflammation. This receptor represents a key component of the brain's endogenous immune checkpoint system.
The CD200-CD200R1 axis is one of the most important endogenous mechanisms for maintaining immunological quiescence in the CNS. Dysregulation of this pathway has been strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, and other neurodegenerative conditions. The therapeutic potential of CD200R1 agonism has made it an attractive target for drug development aimed at modulating neuroinflammation.
This comprehensive review examines the structure and biochemistry of CD200R1, its normal physiological functions in the CNS, the mechanisms by which its dysfunction contributes to neurodegenerative diseases, and current therapeutic strategies targeting this important immune regulatory pathway. [@heneka2015]
Structure
Primary Structure and Domain Architecture
CD200R1 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. The protein consists of:
- Extracellular domain: Approximately 262 amino acids containing two immunoglobulin-like domains (one V-set and one C2-set domain)
- Transmembrane region: 21 amino acids with a conserved cysteine for potential palmitoylation
- Cytoplasmic tail: 220-270 amino acids containing critical signaling motifs
The extracellular region of CD200R1 shares structural features with other immune-inhibitory receptors, but has distinct binding characteristics specific for CD200. The V-set immunoglobulin domain at the N-terminus contains the CD200 binding interface.
Immunoreceptor Tyrosine-Based Inhibitory Motifs (ITIMs)
The cytoplasmic tail of CD200R1 contains multiple ITIMs that mediate its inhibitory function:
- ITIM 1: YXXL/V sequence at position 294-297
- ITIM 2: YXXL/V sequence at position 331-334
- ITIM 3: YXXL/V sequence at position 418-421
These ITIMs recruit protein tyrosine phosphatases (SHP-1 and SHP-2) upon receptor activation, leading to downstream signal inhibition.
Post-Translational Modifications
CD200R1 undergoes several post-translational modifications:
- N-linked glycosylation: Multiple N-glycosylation sites in the extracellular domain
- Palmitoylation: At cysteine residues near the transmembrane domain for membrane localization
- Phosphorylation: Tyrosine residues in ITIMs are phosphorylated upon ligand binding
Structural Basis for Ligand Recognition
The CD200R1 extracellular domain adopts a characteristic immunoglobulin fold:
- V-set domain: N-terminal domain with complementarity-determining regions (CDRs) for CD200 binding
- C2-set domain: Membrane-proximal domain providing structural support
- Linker region: Flexible hinge connecting the two Ig domains
Structural studies have revealed the CD200-CD200R1 interaction interface in detail, showing that a single CD200 molecule can engage two CD200R1 molecules, facilitating receptor clustering and signal transduction. [@wright2010]
Normal Function
CD200R1 Signaling Mechanisms
CD200R1 transduces inhibitory signals through a well-characterized cascade:
Ligand binding: CD200 engagement induces CD200R1 oligomerization
ITIM phosphorylation: Src family kinases phosphorylate tyrosine residues within ITIMs
Phosphatase recruitment: SHP-1 and SHP-2 bind to phosphorylated ITIMs through their SH2 domains
Signal dephosphorylation: Phosphatases dephosphorylate key signaling molecules
Inflammatory suppression: Reduced activation of MAPK, NF-κB, and other pro-inflammatory pathwaysFunctions in the CNS
CD200R1 signaling is essential for maintaining CNS homeostasis:
Microglial Surveillance State: CD200R1 signaling maintains microglia in a ramified surveillance phenotype, preventing unnecessary activation [@ransohoff2016]
Inflammatory Response Limiting: The pathway suppresses pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
Phagocytosis Regulation: Modulates microglial phagocytic activity to prevent excessive debris clearance
Synaptic Pruning Modulation: Regulates complement-mediated synaptic elimination [@song2018]
Neuroprotection: Provides inherent protection against neuroinflammatory insultsCellular Expression Patterns
CD200R1 Expression (cell types with highest expression):
- Microglia (highest expression in the CNS)
- Perivascular macrophages
- Some subsets of peripheral macrophages
- Certain dendritic cell populations
- Low expression on some T cell subsets
Expression Changes in Disease:
- CD200R1 expression is downregulated on microglia in AD and PD
- Reduced receptor levels correlate with disease severity
- Age-related decline in CD200R1 contributes to increased neuroinflammation
Signaling Pathways Regulated by CD200R1
CD200R1 signaling modulates multiple downstream pathways:
Role in Neurodegenerative Diseases
Alzheimer's Disease
CD200R1 Dysregulation in AD
Multiple studies have documented significant alterations in the CD200-CD200R1 pathway in Alzheimer's disease:
- Reduced CD200R1 expression: 40-60% decrease in AD brain tissue
- Impaired ITIM signaling: Reduced phosphatase recruitment and signaling
- Correlation with pathology: Changes correlate with amyloid burden, tau pathology, and cognitive decline
- Microglial phenotype shift: Loss of CD200R1 contributes to inflammatory microglial phenotype [@keren-shaul2017]
Mechanisms of CD200R1 Dysfunction in AD
Amyloid-β Effects: Aβ oligomers contribute to CD200R1 dysfunction through:
- Direct interference with CD200-CD200R1 interaction
- Induction of CD200R1 internalization and degradation
- Competitive binding to CD200R1
- Disruption of receptor clustering required for optimal signaling
Tau Pathology Impact: Hyperphosphorylated tau is associated with further reduction in CD200R1 expression, creating synergistic immune dysregulation. [@hu2022]
Neuroinflammation Feedback Loop: Chronic neuroinflammation leads to:
- Epigenetic silencing of CD200R1 gene expression
- Reduced transcription of CD200R1 mRNA
- Increased receptor degradation
Therapeutic Implications for AD
Strategies targeting CD200R1 in AD include:
CD200R1 Agonists: Recombinant proteins or antibodies that activate CD200R1
Small Molecule Enhancers: Compounds that potentiate CD200R1 signaling
Gene Therapy: AAV-mediated CD200R1 overexpression
Phosphatase Modulators: Enhancing SHP-1/SHP-2 recruitmentPreclinical studies have shown that CD200R1 agonists can:
- Reduce amyloid-induced neuroinflammation
- Improve cognitive function in AD models
- Modulate microglial phagocytosis of Aβ
- Protect against synaptic loss [@yang2021]
Parkinson's Disease
CD200R1 in PD Pathogenesis
In Parkinson's disease, CD200R1 dysregulation contributes to neuroinflammation in affected brain regions:
- Reduced CD200R1: Decreased expression on microglia in substantia nigra
- Enhanced microglial activation: Loss of inhibitory signaling correlates with dopaminergic neuron loss
- α-Synuclein interactions: α-Synuclein oligomers may interfere with CD200R1 signaling
Evidence from Models
- CD200R1 knockout mice show enhanced vulnerability to MPTP-induced parkinsonism
- CD200R1 agonists protect against 6-OHDA toxicity
- CD200R1 deficiency leads to increased inflammatory responses in PD models [@liu2019]
Therapeutic Targeting in PD
Multiple Sclerosis
CD200R1 in MS
In multiple sclerosis and experimental autoimmune encephalomyelitis (EAE):
- CD200R1 expression is reduced on microglia in demyelinating lesions
- Loss of CD200R1 signaling contributes to inflammatory demyelination
- Restoration of CD200-CD200R1 signaling ameliorates EAE [@wu2023]
Mechanisms
The CD200R1 pathway limits:
- T cell activation and infiltration
- Pro-inflammatory cytokine production by microglia
- Demyelination and axonal loss
- Microglial proliferation and activation
Amyotrophic Lateral Sclerosis (ALS)
CD200R1 alterations in ALS:
- Reduced CD200R1 expression in motor cortex and spinal cord
- Correlation with disease progression
- CD200R1 microglial expression changes with disease stage [@li2021]
Stroke and Ischemic Injury
CD200R1 plays protective roles after stroke:
- CD200R1 signaling limits post-ischemic inflammation
- CD200R1 agonists reduce infarct size in models
- The pathway promotes neurological recovery [@wang2019]
Vascular Dementia
CD200R1 dysfunction contributes to vascular cognitive impairment:
- Cerebrovascular disease affects CD200R1 expression
- Cognitive decline correlates with receptor dysfunction
- Therapeutic targeting shows promise [@liu2023]
Signaling Pathways and Mechanisms
CD200R1 Signaling Cascade
CD200R1 signaling involves multiple downstream pathways:
SHP-1/SHP-2 Recruitment: Primary inhibitory signaling through ITIMs
MAPK Inhibition: Reduced ERK activation in response to inflammatory stimuli
NF-κB Suppression: Decreased p65 nuclear translocation
STAT1 Inhibition: Reduced interferon-responsive gene expression
NLRP3 Inflammasome Suppression: Reduced caspase-1 activation and IL-1β productionCross-talk with Other Immune Pathways
CD200R1 signaling intersects with multiple neuroimmune pathways:
- TLR Signaling: CD200R1 can suppress TLR-induced inflammation
- CX3CR1 Pathway: Synergistic with fractalkine signaling
- TREM2 Pathways: Coordinate microglial regulatory mechanisms
- Complement System: Modulates complement-mediated phagocytosis
Cell-Type Specific Effects
CD200R1 signaling has distinct effects on different cell types:
- Microglia: Maintains surveillance state, limits cytokine production, modulates phagocytosis
- Macrophages: Reduces phagocytic activity and antigen presentation
- Perivascular macrophages: Limits CNS immune entry
Therapeutic Targeting
Agonist Approaches
Gene Therapy Approaches
- AAV-CD200R1: Adeno-associated virus-mediated gene delivery
- Lentiviral vectors: Ex vivo modification of cells
- Gene editing: CRISPR-based approaches to enhance CD200R1 expression
Combination Strategies
- CD200R1 agonist + CSF1R inhibitor: Combined immune modulation
- CD200R1 agonist + anti-inflammatory drugs: Synergistic effects
- CD200R1 agonist + neurotrophic factors: Immune modulation + neuroprotection
Biomarkers and Patient Selection
Potential biomarkers for CD200R1-targeted therapy:
- CD200R1 expression levels on peripheral monocytes
- CSF soluble CD200R1 levels
- Genetic polymorphisms in CD200R1 gene
Genetic Variations
The CD200R1 gene contains several polymorphisms that may influence disease risk:
- Promoter variants: Affect CD200R1 expression levels
- Coding variants: May alter receptor function
- 3'UTR variants: Affect mRNA stability
These variations may contribute to inter-individual differences in disease progression and treatment response. [@chen2021]
- [CD200 Gene](/genes/cd200)
- [CD200 Protein](/proteins/CD200-Protein)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Microglia](/cell-types/microglia)
- [CX3CR1 Signaling](/mechanisms/cx3cr1-pathway)
- [TREM2 Signaling](/mechanisms/trem2-signaling-pathway)
- [CSF1R Signaling](/mechanisms/csf1r-pathway)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
Key Publications
[The CD200-CD200R pathway in immune regulation](https://pubmed.ncbi.nlm.nih.gov/12072352/). Trends in Immunology. 2002.
[Neuroinflammation in Alzheimer's disease and Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25646422/). Lancet Neurology. 2015.
[A unique microglia type associated with restricting development of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/28515449/). Cell. 2017.
[The identity and function of microglia in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/30026556/). Nature Immunology. 2018.
[CD200R1 signaling in Parkinson's disease models](https://pubmed.ncbi.nlm.nih.gov/30694242/). Molecular Neurobiology. 2019.
[CD200R1 agonist attenuates cerebral ischemia/reperfusion injury](https://pubmed.ncbi.nlm.nih.gov/31181262/). Brain Research. 2019.
[CD200R1 and neuroinflammation: From basic science to therapeutic applications](https://pubmed.ncbi.nlm.nih.gov/32061847/). Pharmacological Research. 2020.
[CD200R1 agonist restores cognitive function in Alzheimer's models](https://pubmed.ncbi.nlm.nih.gov/34048932/). Neurobiology of Aging. 2021.
[CD200R1 signaling regulates microglial phagocytosis in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/35642187/). J Neuroinflammation. 2022.
[Single-cell analysis of CD200R1 expression in aging brain](https://pubmed.ncbi.nlm.nih.gov/36038654/). Nature Aging. 2022.
[CD200R1 deficiency exacerbates tau pathology](https://pubmed.ncbi.nlm.nih.gov/36309734/). Acta Neuropathol Commun. 2022.
[CD200R1 agonists in Parkinson's disease: preclinical validation](https://pubmed.ncbi.nlm.nih.gov/36951128/). Movement Disorders. 2023.
[CD200R1 and neuroinflammation in multiple sclerosis](https://pubmed.ncbi.nlm.nih.gov/37154123/). Mult Scler. 2023.See Also
- [CD200 Protein](/proteins/CD200-Protein)
- [CX3CR1 Protein](/proteins/cx3cr1-protein)
- [CSF1R Protein](/proteins/csf1r-protein)
- [TREM2 Protein](/proteins/trem2-protein)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Microglial Activation](/mechanisms/microglial-activation)
- [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [UniProt: Q9Y6W5](https://www.uniprot.org/uniprot/Q9Y6W5)
- [PDB: 2OUB](https://www.rcsb.org/structure/2OUB)
- [PDB: 4N5G](https://www.rcsb.org/structure/4N5G)
- [AlphaFold: CD200R1](https://alphafold.ebi.ac.uk/entry/Q9Y6W5)
- [GeneCards: CD200R1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD200R1)
- [IUPHAR: CD200R](https://www.guidetopharmacology.org/GTP/RCDb.html)
Brain Atlas Resources
- [Allen Human Brain Atlas](https://human.brain-map.org/) — protein expression data
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — cell type specific expression
- [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain expression